Table 1.
Prospective study on escalation/de-escalation treatment for LA HNSCC and LA OSCC.
| First author | Year of pubblication | Study Population | Number of Patients | Type of treatment | Primary Endpoint | Primary Endpoint Results |
|---|---|---|---|---|---|---|
| Gillison (21) | 2019 | OSCC P16 positive T1-T2, N2a-N3 or T3-T4, N0- N3 M0 (AJCC VII edition) |
805 | RT (70 Gy) + cisplatin vs RT (70 Gy) + cetuximab | 5-year OS | 84,6% (cisplatin arm) vs 77.9% (cetuximab arm) |
| Sanghera (22) | 2022 | OSCC p16 positive or negative If p16 positive: N2b or above disease and tobacco smoking history ‗ 10 pack/years |
257 | Different arms. ARM 1: RT 70 Gy + cisplatin ARM 3: RT 64 Gy + cisplatin |
EFS and OS | 3-year EFS:72% (ARM 1) v 68% (arm 3) 3-year OS: 79% (ARM 1) vs 74% (arm 3) |
| Zandberg (23) | 2022 | LA HNSCC (p16 positive and p16 negative) If OSCC p16 positive: T4 or N3 or tobacco smoking history ‗ 10 pack/years |
80 | RT (70 Gy) + cisplatin + concomitant pembrolizumab vs RT (70 Gy) + cisplatin + sequential pembrolizumab | 1-year PFS | 89% (sequential arm) vs 82% (concomitant arm) |
|
Tao
(25) |
2023 | LA HNSCC (stage III, IVa, and IVb, limited to T ≥2, N0–3, and M0 (AJCC VII edition); tobacco smoking history of ‗10 pack/years |
96 | RT (70 Gy) + cisplatin + xevinapatin vs RT (70 Gy) + cisplatin + placebo | LRC at 18 months | 54% (xevinapant arm) vs 33% (placebo arm) |
LA HNSCC (locally advanced head and neck squamous cell carcinoma); OSCC (oropharyngeal squamous cell carcinoma); RT (radiotherapy); Gy (Gray); AJCC (American Joint Committee on Cancer); EFS (event free survival); OS (overall survival); LRC (locoregional control).